Nicolas Meyer
Prof Nicolas Meyer is an expert in Dermatology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks Nicolas Meyer in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Nicolas Meyer has authored 262 publications, the most recent in 2026, and is an investigator in 21 clinical trials. SLR score: 1,249 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Hematology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 262
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1. PMID 42056527 — cells, safety, macrophages, neoplasms, drug-related side effects and adverse reactions, therapeutics, ipilimumab, wounds and injuries | Nature Top journal | 2026 | 0 |
| Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA. PMID 41806521 — cells, safety, carcinoma, squamous cell, neoplasms, therapeutics | Eur J Cancer | 2026 | 0 |
| Thermal Preference Plasticity in Ectotherms: Integrating Temperature Affinity and Thermoregulation Precision. PMID 40816256 — body temperature regulation, plastics, temperature | Am Nat | 2025 | 0 |
| TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study. PMID 40098565 — cells, melanoma, neoplasms, immune checkpoint inhibitors, nivolumab, therapeutics, memory, plasma, non-responder | Int J Cancer | 2025 | 0 |
| Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. PMID 38864258 — retrospective studies, prognosis, immunosuppression therapy, skin diseases, therapeutics, neoplasms, disease-free survival, radiotherapy, sexually transmitted diseases, progression-free survival | J Eur Acad Dermatol Venereol | 2024 | 0 |
Clinical Studies 21
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
LeadR Networks
Main global connection map